Topic: Ganaxolone

Background: Alzheimer's disease (AD) is a neurological disease characterised pathologically by loss of synapses and neurones, accumulation of amyloid-beta (Aβ) deposits and formation of neurofibrillary tangles. This results in progressive cognitive impairment as people age. Ganaxolone, a synthetic analogue of allopregnanolone, has shown a protective effect on gliosis associated with demyelination. However, its effect on Aβ deposits and neuronal loss associated with AD is still unknown. Additionally, its effect on liver x receptors (LXR) has not yet been reported. In this study, we investigated